Alhemo FDA Approval History
FDA Approved: Yes (First approved December 20, 2024)
Brand name: Alhemo
Generic name: concizumab-mtci
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Hemophilia A with Inhibitors, Hemophilia B with Inhibitors, Hemophilia A, Hemophilia B
Alhemo (concizumab-mtci) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B with or without inhibitors.
- Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
- hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors
- hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors.
Development timeline for Alhemo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.